• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Chlorthalidone is not superior to hydrochlorothiazide in preventing hypertension-related cardiovascular events

byDavid XiangandKiera Liblik
January 4, 2023
in Cardiology, Chronic Disease, Emergency
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with hypertension who received chlorthalidone did not have a lower occurrence of adverse cardiovascular outcomes compared to patients who received hydrochlorothiazide.

2. Patients who received chlorthalidone did not have a lower occurrence of non-cancer-related deaths than patients who received hydrochlorothiazide. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Thiazide diuretics are often first-line antihypertensive agents used to prevent adverse cardiovascular outcomes in patients with hypertension. Early studies have suggested that chlorthalidone is superior to hydrochlorothiazide in patients with hypertension. Though, recent studies have shown similar efficacy between the two medications. However, there is a gap in knowledge as to understanding whether chlorthalidone, as compared with hydrochlorothiazide reduces the risk of major cardiovascular disease outcomes and non–cancer-related deaths in older patients with hypertension who were receiving hydrochlorothiazide at baseline. Overall, this study found that chlorthalidone did not lead to a lower incidence of major cardiovascular outcomes or non–cancer-related deaths than hydrochlorothiazide in patients with hypertension at doses commonly used in clinical practice. This study was limited by being open-label, which included patients who were assigned to the chlorthalidone group that switched back to hydrochlorothiazide. Nevertheless, these study’s findings are significant, as they demonstrate that chlorthalidone is not superior to hydrochlorothiazide in lowering major cardiovascular outcomes or non-cancer-related deaths in patients with hypertension.

Click to read the study in NEJM

Relevant Reading: Thiazide-like versus Thiazide Diuretics — Finally, an Answer?

RELATED REPORTS

#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

2 Minute Medicine Rewind June 30, 2025

In-Depth [pragmatic open-label trial]: This multicenter, pragmatic, open-label trial was conducted by the Department of Veteran Affairs healthcare system. Patients who were at least 65 years of age and had hypertension and an active prescription for hydrochlorothiazide at a dose of 25 or 50mg per day were eligible for the study. Patients who were taking blood-pressure medication that contained hydrochlorothiazide combined with other agents were excluded from the study. The primary outcome measured was the first occurrence of a composite outcome consisting of a nonfatal cardiovascular disease event or non–cancer-related death, assessed in a time-to-event analysis. Nonfatal cardiovascular disease events were nonfatal myocardial infarction, stroke, hospitalization for heart failure, or urgent coronary revascularization for unstable angina. Outcomes of the primary analysis were assessed via unadjusted log-rank tests that were stratified according to the Veteran Affairs healthcare system. Based on the primary analysis, with a median follow-up of 2.4 years, there was little difference in the occurrence of primary-outcome events between the chlorthalidone group (702 patients [10.4%]) and the hydrochlorothiazide group (675 patients [10.0%]) (hazard ratio, 1.04; 95% confidence interval, 0.94 to 1.16). There were no between-group differences in the occurrence of any of the components of the primary outcome. The incidence of hypokalemia was higher in the chlorthalidone group than in the hydrochlorothiazide group (6.0% vs. 4.4%; p<0.001). Overall, this study demonstrates that patients receiving chlorthalidone did not have a lower occurrence of major cardiovascular outcome events or non-cancer-related deaths than patients receiving hydrochlorothiazide.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: blood pressurecardiologycardiovascular diseasechlorthalidonechronic diseaseemergencyhydrochlorothiazidehypertensionmajor adverse cardiovascular events (MACE)
Previous Post

COVID-19 pandemic associated with decreased emergency department access for sexual assaults

Next Post

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

RelatedReports

#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
All Specialties

#VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation

July 3, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Weekly Rewinds

2 Minute Medicine Rewind June 30, 2025

June 30, 2025
Chronic Disease

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

June 27, 2025
Next Post
#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

2 Minute Medicine Rewind November 23 – November 30, 2014

Vaccines for Zaire Ebola virus disease are safe and generate an immune response

Similar outcomes after supracervical vs. total hysterectomy

Characterization of prognostic markers of residual neoplastic disease following hysterectomy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.